Login
Login

  • DataFirst Home
  • Open Data Portal
  • Collections
  • Citations
  • Contact us
    Home / Data Portal / AZ / ZAF-UKZN-CU-AZ-2008-2012-V1 / variable [F1]
AZ

Asenze Study 2008-2012, Waves 1 and 2

South Africa, 2008 - 2012
Get Microdata
Reference ID
zaf-ukzn-cu-az-2008-2012-v1
Producer(s)
University of KwaZulu-Natal, Columbia University
Collections
Asenze Study
Metadata
Documentation in PDF DDI/XML JSON
Created on
May 02, 2025
Last modified
May 12, 2025
Page views
721
Downloads
7
  • Study Description
  • Data Description
  • Downloads
  • Get Microdata
  • Data files
  • asenze-2008-2012-w1-2-v1

CHILD-Hemoglobin: (CHVCT8W1)

Data file: asenze-2008-2012-w1-2-v1

Overview

Valid: 1581
Invalid: 0
Minimum: 6.1
Maximum: 99
Type: Discrete
Decimal: 0
loc_start_pos: 1573
loc_end_pos: 1575
Width: 3
Range: 6.1 - 99
Format: Numeric

Questions and instructions

Categories
Value Category Cases
6.1 2
0.1%
6.5 2
0.1%
6.7 1
0.1%
6.8 1
0.1%
7 1
0.1%
7.3 1
0.1%
7.5 1
0.1%
7.6 2
0.1%
7.7 5
0.3%
7.9 3
0.2%
8 2
0.1%
8.1 5
0.3%
8.2 6
0.4%
8.3 4
0.3%
8.4 3
0.2%
8.5 9
0.6%
8.6 4
0.3%
8.7 5
0.3%
8.8 7
0.4%
8.9 11
0.7%
9 17
1.1%
9.1 17
1.1%
9.2 18
1.1%
9.3 22
1.4%
9.4 24
1.5%
9.5 22
1.4%
9.6 16
1%
9.7 26
1.6%
9.8 23
1.5%
9.9 27
1.7%
10 30
1.9%
10.1 27
1.7%
10.2 46
2.9%
10.3 42
2.7%
10.4 55
3.5%
10.5 52
3.3%
10.6 64
4%
10.7 60
3.8%
10.8 51
3.2%
10.9 45
2.8%
11 53
3.4%
11.1 59
3.7%
11.2 54
3.4%
11.3 55
3.5%
11.4 48
3%
11.5 61
3.9%
11.6 60
3.8%
11.7 48
3%
11.8 35
2.2%
11.9 53
3.4%
12 37
2.3%
12.1 28
1.8%
12.2 35
2.2%
12.3 25
1.6%
12.4 33
2.1%
12.5 21
1.3%
12.6 13
0.8%
12.7 11
0.7%
12.8 18
1.1%
12.9 15
0.9%
13 4
0.3%
13.1 9
0.6%
13.2 8
0.5%
13.3 6
0.4%
13.4 4
0.3%
13.5 1
0.1%
13.6 6
0.4%
13.7 1
0.1%
13.8 5
0.3%
13.9 1
0.1%
14.1 2
0.1%
14.3 3
0.2%
14.4 1
0.1%
14.5 1
0.1%
16 1
0.1%
88 refused to allow venepuncture 4
0.3%
99 unknown 3
0.2%
Warning: these figures indicate the number of cases found in the data file. They cannot be interpreted as summary statistics of the population of interest.
Back to Catalog
DataFirst

© DataFirst, All Rights Reserved.